Chen, Elisabeth D.
Liz started her PhD in Mathew Garnett's group in 2015. There she is working on linking cellular phenotypes with drug response in cancer cell lines, in particular looking at the reliance on anti-apoptotic proteins and DNA repair efficiency.
My work is built on the extensive genomic characterisation and drug screening of human cancer cell lines completed within the Translational Cancer Genomics group. To date, our group has screened over 600 anti-cancer drugs across a genomicaly annotated panel of > 1,000 human cancer cell lines with the goal to identify therapeutic biomarkers that can predict response to anti-cancer drugs. My particular aims are to characterise our collection of cancer cell lines in terms of apoptotic priming and DNA repair efficiency. I am hoping to link these cellular phenotypes with the genomic background of the cancer cell lines, which in turn will our understanding of the mode of action of targetted anti-cancer drugs. In addition to my main project, I am also interested in studying how the growth rate of cancer cell lines impacts on drug response.
Prior to coming to the Sanger Institute, I obtained my BSc from Imperial College London, during which I completed a year-long research internship at teh Royal Botanic Gardens, Kew, where I looked at the evolution of the morphology of plant stomata.